Eli Lilly’s stock (NYSE: LLY) soared nearly 50%, in the past six months, driven not only by outstanding earnings and a notable margin increase, but also by reaching a $1T market cap and excitement surrounding revolutionary GLP-1 and oral drug potentials. Let’s explore the factors behind this extraordinary surge. Separately, read about the turmoil in Bitcoin: Before Bitcoin Hits $50,000, Ask This One Question.
Here’s an analytical overview of stock movement based on key contributing metrics.
What is transpiring here? The stock climbed 49%, fueled by an 8.7% revenue increase, a 14% growth in net margin, and a 20% rise in P/E multiples over the last six months. Let’s delve into the main movements that led to these enhancements.
Opinion: We currently consider LLY stock appealing yet volatile. Why is that? Check out the entire story. Read Buy or Sell LLY Stock to understand what underpins our present viewpoint.
Risk: A reliable method for assessing risk in LLY is by looking at how much it dropped during significant market downturns. It fell roughly 43% during the Dot-Com Bubble and over 50% in the Global Financial Crisis. Even during less severe periods like the 2018 Correction, the COVID-19 pandemic, and the recent Inflation Shock, the stock still declined by about 18-22%. Thus, while LLY may appear robust on paper, historical patterns indicate it’s not exempt from steep sell-offs when the market declines.
LLY stock may have experienced robust growth lately, but investing in a single stock without a comprehensive, detailed analysis carries risks. The Trefis High Quality (HQ) Portfolio, encompassing 30 stocks, has a history of comfortably outperforming its benchmark, which includes all three — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? Collectively, HQ Portfolio stocks have provided superior returns with less risk compared to the benchmark index, offering a smoother ride, as shown in HQ Portfolio performance metrics.
